{"id":"pd-1-antibody","safety":{"commonSideEffects":[{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Immune-related adverse events (pneumonitis, hepatitis, colitis)"},{"rate":null,"effect":"Rash"}]},"_chembl":{"chemblId":"CHEMBL1474985","moleculeType":"Small molecule","molecularWeight":"476.24"},"_dailymed":null,"mechanism":{"_ai_source":"anthropic-haiku","explanation":"PD-1 (programmed death receptor 1) is an immune checkpoint that normally suppresses T cell activity. Tumors exploit this by expressing PD-L1 and PD-L2 ligands. By binding to PD-1, this monoclonal antibody prevents ligand engagement, restoring T cell proliferation, activation, and cytotoxic function against malignant cells. This mechanism has proven effective across multiple cancer types.","oneSentence":"A PD-1 antibody blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, releasing immune checkpoint inhibition and allowing T cells to recognize and attack cancer.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:50:58.973Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Advanced or metastatic solid tumors (specific indications under investigation in phase 3)"}]},"trialDetails":[{"nctId":"NCT05768932","phase":"PHASE1","title":"BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"SillaJen, Inc.","startDate":"2022-12-14","conditions":"Advanced Solid Tumor, TNBC - Triple-Negative Breast Cancer, Gastric Cancer","enrollment":260},{"nctId":"NCT06841354","phase":"PHASE3","title":"A Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Triple-Negative Breast Cancer (MK-2870-011/TroFuse-011)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-03-16","conditions":"Triple Negative Breast Neoplasms","enrollment":1000},{"nctId":"NCT07395258","phase":"PHASE1","title":"A Study to Test Different Doses of BI 3923948 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)","status":"NOT_YET_RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2026-03-30","conditions":"Solid Tumors","enrollment":60},{"nctId":"NCT03620019","phase":"PHASE2","title":"Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma","status":"COMPLETED","sponsor":"UNC Lineberger Comprehensive Cancer Center","startDate":"2018-09-10","conditions":"Melanoma Stage Iii, Melanoma Stage Iv, Melanoma","enrollment":25},{"nctId":"NCT02834013","phase":"PHASE2","title":"Nivolumab and Ipilimumab in Treating Patients With Rare Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2017-01-30","conditions":"Acinar Cell Carcinoma, Adenoid Cystic Carcinoma, Adrenal Cortical Carcinoma","enrollment":818},{"nctId":"NCT04840589","phase":"PHASE1","title":"Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors","status":"SUSPENDED","sponsor":"National Cancer Institute (NCI)","startDate":"2022-02-02","conditions":"Metastatic Malignant Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Platinum-Resistant Ovarian Carcinoma","enrollment":66},{"nctId":"NCT06594991","phase":"PHASE2","title":"A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With Melanoma","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-09-10","conditions":"Advanced Melanoma","enrollment":88},{"nctId":"NCT03816358","phase":"PHASE1","title":"Testing the Combination of Anetumab Ravtansine With Either Nivolumab, Nivolumab and Ipilimumab, or Gemcitabine and Nivolumab in Advanced Pancreatic Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2019-12-09","conditions":"Pancreatic Adenocarcinoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8","enrollment":74},{"nctId":"NCT04579224","phase":"PHASE3","title":"Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-06-28","conditions":"Metastatic Bladder Urothelial Carcinoma, Metastatic Urothelial Carcinoma, Refractory Bladder Urothelial Carcinoma","enrollment":184},{"nctId":"NCT04785820","phase":"PHASE2","title":"A Study of Lomvastomig (RO7121661) and Tobemstomig (RO7247669) Compared With Nivolumab in Participants With Advanced or Metastatic Squamous Cell Carcinoma of the Esophagus","status":"COMPLETED","sponsor":"Hoffmann-La Roche","startDate":"2021-06-25","conditions":"Advanced or Metastatic Esophageal Squamous Cell Carcinoma","enrollment":190},{"nctId":"NCT06425926","phase":"PHASE1, PHASE2","title":"Safety and Tolerability Study of GIM-531 in Advanced Solid Tumors","status":"RECRUITING","sponsor":"Georgiamune Inc","startDate":"2024-05-09","conditions":"Melanoma Stage IV, Solid Tumor","enrollment":117},{"nctId":"NCT05763004","phase":"PHASE1","title":"A Clinical Study to Evaluate the Safety, Tolerability and Efficacy of IOS-1002 Administered Alone and in Combination With Pembrolizumab, a PD-1 Monoclonal Antibody in Advanced Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"ImmunOs Therapeutics AG","startDate":"2023-03-15","conditions":"Solid Tumor, Adult","enrollment":140},{"nctId":"NCT02298959","phase":"PHASE1","title":"Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2015-04-08","conditions":"Clinical Stage IV Cutaneous Melanoma AJCC v8, Metastatic Colorectal Carcinoma, Metastatic Malignant Solid Neoplasm","enrollment":59},{"nctId":"NCT06953323","phase":"PHASE1, PHASE2","title":"A Phase I/II Study of WJB001 Combination Therapy on Safety and Efficacy for Advanced Solid Tumors","status":"RECRUITING","sponsor":"Wigen Biomedicine Technology (Shanghai) Co., Ltd.","startDate":"2025-07-10","conditions":"Advanced Solid Tumor","enrollment":86},{"nctId":"NCT07466238","phase":"NA","title":"HAIC Plus Systemic Therapy as De-escalation Therapy Strategy for Biliary Tract Cancer","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2026-03-15","conditions":"Biliary Tract Cancer (BTC)","enrollment":40},{"nctId":"NCT05870761","phase":"PHASE2","title":"Combination Niraparib and Dostarlimab Therapy for Recurrent or Persistent Uterine Serous Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Casey Cosgrove","startDate":"2023-10-17","conditions":"Recurrent Endometrial Serous Adenocarcinoma","enrollment":8},{"nctId":"NCT04214249","phase":"PHASE2","title":"BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid Leukemia","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2021-02-17","conditions":"Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Acute Myeloid Leukemia Post Cytotoxic Therapy","enrollment":49},{"nctId":"NCT07422363","phase":"PHASE1","title":"Testing the Combination of Anti-cancer Drugs Actimab-A and Cemiplimab (REGN2810) to Improve Outcomes for Patients With Recurrent Glioblastoma","status":"NOT_YET_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2026-06-28","conditions":"Recurrent Glioblastoma, IDH-Wildtype, Recurrent Gliosarcoma, Recurrent WHO Grade 4 Glioma","enrollment":30},{"nctId":"NCT07288034","phase":"PHASE2","title":"Immunotherapy Biomarkers to Predict First-line PD(L)1-based Immunotherapy Response and Selection of Second-line Treatment in Stage IIIB-IV Non-small Cell Lung Cancer, IMMUNO-BIOMAP Trial","status":"NOT_YET_RECRUITING","sponsor":"City of Hope Medical Center","startDate":"2026-09-21","conditions":"Lung Non-Small Cell Carcinoma, Stage IIIB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8","enrollment":535},{"nctId":"NCT05982522","phase":"PHASE1, PHASE2","title":"IN10018 Combination Therapy in Previously-treated Solid Tumors","status":"WITHDRAWN","sponsor":"InxMed (Shanghai) Co., Ltd.","startDate":"2025-08-13","conditions":"Solid Tumor","enrollment":""},{"nctId":"NCT05287113","phase":"PHASE2","title":"Study of Retinfanlimab in Combination With INCAGN02385 and INCAGN02390 as First-Line Treatment in Participants With PD-L1-Positive (CPS ≥ 1) Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck","status":"ACTIVE_NOT_RECRUITING","sponsor":"Incyte Biosciences International Sàrl","startDate":"2022-11-14","conditions":"Head and Neck Cancer","enrollment":176},{"nctId":"NCT04234113","phase":"PHASE1","title":"Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors","status":"TERMINATED","sponsor":"SOTIO Biotech AG","startDate":"2019-06-13","conditions":"Thyroid Cancer, Renal Cell Carcinoma, Non Small Cell Lung Cancer","enrollment":115},{"nctId":"NCT06418724","phase":"PHASE2","title":"Neoadjuvant PD-1 Inhibitor and EGFR Inhibitor in Locally Advanced Cutaneous Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Melanoma and Skin Cancer Trials Limited","startDate":"2026-07-30","conditions":"Locally Advanced Cutaneous Squamous Cell Carcinoma","enrollment":27},{"nctId":"NCT03894215","phase":"PHASE2","title":"RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer","status":"TERMINATED","sponsor":"Agenus Inc.","startDate":"2019-06-01","conditions":"Cervical Cancer","enrollment":211},{"nctId":"NCT06325683","phase":"PHASE2","title":"Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2024-11-08","conditions":"Progressive Glioblastoma, Recurrent Glioblastoma","enrollment":184},{"nctId":"NCT03017820","phase":"PHASE1","title":"A Vaccine (VSV-hIFNβ-NIS) With or Without Cyclophosphamide and Combinations of Ipilimumab, Nivolumab, and Cemiplimab in Treating Relapsed or Refractory Multiple Myeloma, Acute Myeloid Leukemia or Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2017-04-04","conditions":"B-Cell Non-Hodgkin Lymphoma, Histiocytic and Dendritic Cell Neoplasm, Myelodysplastic Syndrome","enrollment":127},{"nctId":"NCT07365839","phase":"PHASE1","title":"Cemiplimab +/- Fianlimab Post Y90 Radioembolization in Patients With Hepatocellular Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"Virginia Commonwealth University","startDate":"2026-07-01","conditions":"Hepatocellular Carcinoma","enrollment":20},{"nctId":"NCT07492914","phase":"PHASE2","title":"Neoadjuvant Sacituzumab Govitecan Plus Tagitanlimab for Resectable Head and Neck Squamous Cell Carcinoma","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-03-20","conditions":"Resected Head and Neck Cancer","enrollment":30},{"nctId":"NCT03361852","phase":"PHASE1","title":"Personalized Neoantigen Cancer Vaccine + Pembrolizumab After Rituximab for Follicular Lymphoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Dana-Farber Cancer Institute","startDate":"2022-03-14","conditions":"Follicular Lymphoma","enrollment":20},{"nctId":"NCT06925724","phase":"PHASE2","title":"A Study of Ivonescimab in People With Endometrial and Cervical Cancers","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2025-04-04","conditions":"Endometrial Cancer, Cervical Cancer","enrollment":50},{"nctId":"NCT07281924","phase":"PHASE1, PHASE2","title":"Hepzato Kit and Opdualag for Metastatic Melanoma and Liver Metastasis","status":"RECRUITING","sponsor":"University of Wisconsin, Madison","startDate":"2026-04","conditions":"Metastatic Melanoma, Liver Metastases","enrollment":15},{"nctId":"NCT06926868","phase":"PHASE2, PHASE3","title":"A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)","status":"RECRUITING","sponsor":"Bristol-Myers Squibb","startDate":"2025-09-11","conditions":"Breast Neoplasms","enrollment":500},{"nctId":"NCT03568058","phase":"PHASE1","title":"Personalized Immunotherapy in Adults With Advanced Cancers Immunotherapy in Adults With Advanced Cancers","status":"COMPLETED","sponsor":"Aaron Miller","startDate":"2018-07-26","conditions":"Advanced Cancer","enrollment":25},{"nctId":"NCT05929664","phase":"PHASE2","title":"Cemiplimab Plus Fianlimab for the Treatment of Locally Advanced Head and Neck Basal Cell Carcinoma Before Surgery","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2023-07-05","conditions":"Locally Advanced Basal Cell Carcinoma, Basal Cell Carcinoma","enrollment":70},{"nctId":"NCT04995523","phase":"PHASE1, PHASE2","title":"A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC","status":"ACTIVE_NOT_RECRUITING","sponsor":"AstraZeneca","startDate":"2021-09-14","conditions":"Non-Small-Cell Lung Carcinoma","enrollment":212},{"nctId":"NCT07489534","phase":"PHASE2","title":"Study of PD-1Ab21-BCMA CAR-T Therapy for Consolidation of Multiple Myelomawith Renal Dysfunction","status":"RECRUITING","sponsor":"Daihong Liu","startDate":"2025-09-29","conditions":"Multiple Myeloma","enrollment":25},{"nctId":"NCT03288545","phase":"PHASE1, PHASE2","title":"A Study of Enfortumab Vedotin Alone or With Other Therapies for Treatment of Urothelial Cancer","status":"TERMINATED","sponsor":"Astellas Pharma Global Development, Inc.","startDate":"2017-10-11","conditions":"Carcinoma, Transitional Cell, Urinary Bladder Neoplasms, Urologic Neoplasms","enrollment":348},{"nctId":"NCT05152147","phase":"PHASE3","title":"A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jazz Pharmaceuticals","startDate":"2021-12-02","conditions":"Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma","enrollment":920},{"nctId":"NCT06781125","phase":"PHASE1, PHASE2","title":"One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors","status":"NOT_YET_RECRUITING","sponsor":"Immorna Biotherapeutics, Inc.","startDate":"2026-03-18","conditions":"Malignant Solid Tumors","enrollment":72},{"nctId":"NCT07490990","phase":"","title":"A Real-World, Single-Arm Study Protocol of Disitamab Vedotin in Combination With Immunotherapy and Multimodal Radiation Therapy for HER2-Positive Advanced Gastric Cancer: After Second-Line Treatment Failure","status":"NOT_YET_RECRUITING","sponsor":"West China Hospital","startDate":"2026-06","conditions":"HER2-positive Advanced Gastric Cancer or Gastroesophageal Junction Adenocarcinoma","enrollment":30},{"nctId":"NCT07488533","phase":"PHASE2","title":"Comparing the Combination of Sullumab and Fruquintinib in Postoperative Adjuvant Therapy for High Recurrence Risk Non Transparent Renal Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-08-01","conditions":"Non-Clear Cell Renal Cell Carcinoma","enrollment":40},{"nctId":"NCT05123482","phase":"PHASE1, PHASE2","title":"A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2021-10-18","conditions":"Breast Cancer, Biliary Tract Carcinoma, Ovarian Cancer","enrollment":460},{"nctId":"NCT06580938","phase":"PHASE1","title":"A Study to Learn About PF-07921585 Alone or With Other Anti-cancer Medicines in People With Cancer","status":"TERMINATED","sponsor":"Pfizer","startDate":"2024-11-11","conditions":"Non Small Cell Lung Cancer, Bladder Cancer, Renal Cell Carcinoma","enrollment":4},{"nctId":"NCT04462406","phase":"PHASE2","title":"Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"ECOG-ACRIN Cancer Research Group","startDate":"2021-02-09","conditions":"Advanced Melanoma, Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage IV Cutaneous Melanoma AJCC v8","enrollment":150},{"nctId":"NCT04387084","phase":"PHASE1","title":"Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Southern California","startDate":"2020-08-12","conditions":"Advanced Malignant Skin Neoplasm, Metastatic Malignant Skin Neoplasm","enrollment":10},{"nctId":"NCT07487519","phase":"PHASE2","title":"Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Henlius Biotech","startDate":"2026-04-25","conditions":"Breast Cancer (Triple Negative Breast Cancer (TNBC))","enrollment":180},{"nctId":"NCT06897579","phase":"PHASE2","title":"Carboplatin/Cisplatin + Etoposide + Benmelstobart Sequential Benmelstobart Combined With Anlotinib Versus Carboplatin/Cisplatin + Etoposide + Tislelizumab Sequential Tislelizumab in the Treatment of Extensive Stage Small Cell Lung Cancer","status":"RECRUITING","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2025-04-07","conditions":"Extensive Stage Small Cell Lung Cancer","enrollment":134},{"nctId":"NCT07218003","phase":"PHASE1","title":"A Phase 1/1b of RNDO-564 Single Agent or in Combination With Pembrolizumab in Bladder Cancer and Other Solid Tumors Associated With Nectin-4","status":"ENROLLING_BY_INVITATION","sponsor":"Rondo Therapeutics","startDate":"2025-11-17","conditions":"Non Small Cell Lung Cancer, Cervical Cancer, Head and Neck Squamous Cell Cancer","enrollment":149},{"nctId":"NCT07488572","phase":"PHASE2","title":"Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study","status":"ENROLLING_BY_INVITATION","sponsor":"Sun Yat-sen University","startDate":"2025-11-01","conditions":"Renal Cell Carcinoma (RCC), Metastatic Clear Cell Renal Cell Carcinoma","enrollment":60},{"nctId":"NCT06827236","phase":"PHASE1, PHASE2","title":"A Clinical Study to Find the Optimal Dose of an Investigational Treatment Called BNT323 When Used in Combination With Another Investigational Treatment, BNT327, and to Test if That Combination Treatment is Safe and Beneficial for Patients With Advanced Breast Cancer","status":"RECRUITING","sponsor":"BioNTech SE","startDate":"2025-04-23","conditions":"Locally Advanced Breast Cancer, Unresectable Breast Carcinoma, Metastatic Breast Cancer","enrollment":380},{"nctId":"NCT07320963","phase":"PHASE1, PHASE2","title":"Chidamide in Combination With Toripalimab and Anlotinib in Recurrent/Metastatic Nasopharyngeal Carcinoma.","status":"NOT_YET_RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2026-03-31","conditions":"Nasopharyngeal Carcinoma","enrollment":52},{"nctId":"NCT05319730","phase":"PHASE1, PHASE2","title":"A Study to Evaluate Investigational Agents With or Without Pembrolizumab (MK-3475) in Participants With Advanced Esophageal Cancer Previously Exposed to Programmed Cell Death 1 Protein (PD-1)/ Programmed Cell Death Ligand 1 (PD-L1) Treatment (MK-3475-06B)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2023-05-16","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":230},{"nctId":"NCT03521830","phase":"PHASE2","title":"Nivolumab Alone or Plus Relatlimab or Ipilimumab for Patients With Locally-Advanced Unresectable or Metastatic Basal Cell Carcinoma","status":"RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-11-27","conditions":"Basal Cell Carcinoma","enrollment":57},{"nctId":"NCT07481058","phase":"PHASE2","title":"KC1036 in Combination With PD-1 Antibody and Platinum-based Chemotherapy for First-line Advanced Esophageal Cancer","status":"RECRUITING","sponsor":"Beijing Konruns Pharmaceutical Co., Ltd.","startDate":"2025-12-12","conditions":"Esophageal Squamous Cell Carcinoma (ESCC)","enrollment":60},{"nctId":"NCT07216703","phase":"PHASE3","title":"A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2026-01-19","conditions":"Cervical Cancer","enrollment":1023},{"nctId":"NCT05661955","phase":"PHASE1, PHASE2","title":"A Study to Investigate the Antitumor Activity, Safety, Tolerability, and Pharmacokinetics of BGB-A445 in Combination With Tislelizumab in Participants With Select Advanced Solid Tumors.","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2023-01-09","conditions":"Urothelial Carcinoma, Renal Cell Carcinoma, Melanoma","enrollment":113},{"nctId":"NCT07380984","phase":"PHASE2","title":"PD-1 Antibody-based Therapy With Concurrent RT for Early-stage NKTCL","status":"RECRUITING","sponsor":"Ruijin Hospital","startDate":"2026-03","conditions":"Natural Killer/T-cell Lymphoma","enrollment":47},{"nctId":"NCT07277439","phase":"PHASE2","title":"Phase II Trial of Neoadjuvant Thymalfasin, PD-1 Inhibitor, and Chemoradiotherapy for cStage III GEJ Adenocarcinoma","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-12-16","conditions":"Gastric Cancer","enrollment":48},{"nctId":"NCT07484022","phase":"PHASE1","title":"Study of GB-4362 With Enfortumab Vedotin and Pembrolizumab for Advanced Urothelial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Generate Biomedicines","startDate":"2026-03","conditions":"Advanced Urothelial Cancer, Metastatic Urothelial Carcinoma","enrollment":37},{"nctId":"NCT05981703","phase":"PHASE1","title":"A Study Investigating BGB-26808 Alone or in Combination With Tislelizumab in Participants With Advanced Solid Tumors","status":"RECRUITING","sponsor":"BeOne Medicines","startDate":"2023-09-21","conditions":"Advanced Solid Tumor, Solid Tumor","enrollment":217},{"nctId":"NCT03491683","phase":"PHASE1, PHASE2","title":"INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Inovio Pharmaceuticals","startDate":"2018-05-31","conditions":"Glioblastoma","enrollment":52},{"nctId":"NCT04181788","phase":"PHASE1, PHASE2","title":"Sasanlimab (PF-06801591, PD-1 Inhibitor) in Participants With Advanced Malignancies","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-03-18","conditions":"Advanced Malignancies, Non-small-cell Lung Cancer","enrollment":155},{"nctId":"NCT05689853","phase":"PHASE1, PHASE2","title":"Study of AK119 Combined With AK112 in Patients With Advanced Solid Tumors","status":"RECRUITING","sponsor":"Akeso","startDate":"2023-04-14","conditions":"Solid Tumor, Adult","enrollment":87},{"nctId":"NCT06357806","phase":"NA","title":"The Treatment of PD-1 Antibody Combined With Peg-IFNα in NAs-suppressed CHB Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Beijing 302 Hospital","startDate":"2024-05-17","conditions":"Chronic Hepatitis B","enrollment":45},{"nctId":"NCT07479485","phase":"PHASE1, PHASE2","title":"MRG006A Combination Therapy for Advanced Hepatocellular Carcinoma (Phase I/II)","status":"NOT_YET_RECRUITING","sponsor":"Lepu Biopharma Co., Ltd.","startDate":"2026-04","conditions":"Hepatocellular Carcinoma","enrollment":160},{"nctId":"NCT04379635","phase":"PHASE3","title":"Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in Non-Small Cell Lung Cancer (NSCLC)","status":"ACTIVE_NOT_RECRUITING","sponsor":"BeiGene","startDate":"2020-05-29","conditions":"Non Small Cell Lung Cancer","enrollment":453},{"nctId":"NCT04143711","phase":"PHASE1, PHASE2","title":"Study of DF1001 in Patients With Advanced Solid Tumors","status":"COMPLETED","sponsor":"Dragonfly Therapeutics","startDate":"2019-11-11","conditions":"Solid Tumor, Adult","enrollment":270},{"nctId":"NCT05187182","phase":"PHASE1","title":"CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2023-06-02","conditions":"Gastric Cancer, Esophageal Cancer, Stomach Cancer","enrollment":42},{"nctId":"NCT05098132","phase":"PHASE1, PHASE2","title":"Study of STK-012 Alone and With Other Treatments in Patients With Advanced Lung Cancer and Other Cancers","status":"RECRUITING","sponsor":"Synthekine","startDate":"2022-01-25","conditions":"Advanced Solid Tumor, Non Small Cell Lung Cancer, Untreated Advanced NSCLC","enrollment":364},{"nctId":"NCT04140500","phase":"PHASE1, PHASE2","title":"Dose Escalation Study of a PD1-LAG3 Bispecific Antibody in Patients With Advanced and/or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Hoffmann-La Roche","startDate":"2019-11-11","conditions":"Solid Tumors, Metastatic Melanoma, Non-small Cell Lung Cancer","enrollment":170},{"nctId":"NCT04902040","phase":"PHASE1, PHASE2","title":"Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies","status":"TERMINATED","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-04-14","conditions":"Advanced Bladder Carcinoma, Advanced Lung Non-Small Cell Carcinoma, Advanced Malignant Solid Neoplasm","enrollment":19},{"nctId":"NCT04699188","phase":"PHASE1, PHASE2","title":"Study of JDQ443 in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Novartis Pharmaceuticals","startDate":"2021-02-24","conditions":"KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small-Cell Lung, Carcinoma, Colorectal","enrollment":344},{"nctId":"NCT03585465","phase":"PHASE1, PHASE2","title":"Nivolumab in Combination With Metronomic Chemotherapy in Paediatrics Refractory / Relapsing Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Oscar Lambret","startDate":"2019-03-26","conditions":"Childhood Solid Tumor","enrollment":63},{"nctId":"NCT04375384","phase":"PHASE2","title":"Cetuximab After Immunotherapy for the Treatment of Head and Neck Squamous Cell Cancer","status":"RECRUITING","sponsor":"Wake Forest University Health Sciences","startDate":"2020-07-01","conditions":"Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Metastatic Head-and-neck Squamous-cell Carcinoma","enrollment":38},{"nctId":"NCT05702229","phase":"PHASE2","title":"Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2023-01-16","conditions":"Gastric Cancer","enrollment":163},{"nctId":"NCT03799445","phase":"PHASE2","title":"Ipilimumab, Nivolumab, and Radiation Therapy in Treating Patients With HPV Positive Advanced Oropharyngeal Squamous Cell Carcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2019-07-25","conditions":"Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Human Papillomavirus Positive Oropharyngeal Squamous Cell Carcinoma","enrollment":37},{"nctId":"NCT05155332","phase":"PHASE1","title":"A Study to Test Different Doses of BI 1831169 Alone and in Combination With an Anti-PD-1 Antibody in People With Different Types of Advanced Cancer (Solid Tumors)","status":"RECRUITING","sponsor":"Boehringer Ingelheim","startDate":"2022-03-28","conditions":"Solid Tumors","enrollment":190},{"nctId":"NCT07161414","phase":"PHASE1","title":"A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-11-25","conditions":"Advanced Solid Tumors","enrollment":40},{"nctId":"NCT05738694","phase":"PHASE3","title":"Neoadjuvant of Axitinib Plus PD-1 to Improve Disease Free Survival of Patients With Renal Cell Carcinoma","status":"RECRUITING","sponsor":"ZHOU FANGJIAN","startDate":"2023-04-19","conditions":"Renal Cell Carcinoma, Neoadjuvant","enrollment":298},{"nctId":"NCT02504372","phase":"PHASE3","title":"Study of Pembrolizumab (MK-3475) vs Placebo for Participants With Non-small Cell Lung Cancer After Resection With or Without Standard Adjuvant Therapy (MK-3475-091/KEYNOTE-091)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2015-11-06","conditions":"Non-small Cell Lung Cancer","enrollment":1177},{"nctId":"NCT07115043","phase":"PHASE1, PHASE2","title":"A Study to Investigate Safety of AZD6750 in Adult Participants With Select Advanced or Metastatic Solid Tumors","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2025-07-29","conditions":"Melanoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma (Skin)","enrollment":60},{"nctId":"NCT07476326","phase":"PHASE1","title":"Pharmacokinetics, Safety, and Immunogenicity Comparison of Bmab1700 and Opdivo® as Adjuvant Monotherapy in Participants With Melanoma","status":"NOT_YET_RECRUITING","sponsor":"Biocon Biologics UK PLC","startDate":"2026-06-01","conditions":"Melanoma","enrollment":120},{"nctId":"NCT07403136","phase":"PHASE2","title":"Vebrekotuzumab ± Anti-PD-1 in Pretreated Advanced ESCC","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-02-01","conditions":"Esophageal Squamous Cell Carcinoma","enrollment":52},{"nctId":"NCT04943848","phase":"PHASE1","title":"rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMG","status":"RECRUITING","sponsor":"Ann & Robert H Lurie Children's Hospital of Chicago","startDate":"2022-01-10","conditions":"Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, H3 K27M-Mutant","enrollment":36},{"nctId":"NCT07474064","phase":"PHASE2","title":"Probiotics Combined With Targeted Therapy Plus Immunotherapy in Bladder-Preserving Setting for Patients With MIBC","status":"NOT_YET_RECRUITING","sponsor":"chenxu","startDate":"2026-03-26","conditions":"Muscle Invasive Bladder Cancer (MIBC)","enrollment":146},{"nctId":"NCT02998268","phase":"PHASE2","title":"Study of Pembrolizumab in Locally Advanced Esophageal Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Medical College of Cornell University","startDate":"2017-03-07","conditions":"Esophageal Adenocarcinoma","enrollment":42},{"nctId":"NCT06840834","phase":"PHASE2","title":"Evaluating Ivonescimab as a Potential Treatment for Pleural Mesothelioma Patients Whose Cancer Has Returned After Previous Immunotherapy and Chemotherapy","status":"RECRUITING","sponsor":"Intergroupe Francophone de Cancerologie Thoracique","startDate":"2025-06-30","conditions":"Pleural Mesotheliomas","enrollment":38},{"nctId":"NCT07472153","phase":"PHASE2, PHASE3","title":"PD-1 (Programmed Death-1) Versus PD-L1 (Programmed Death-ligand 1) Immune Check Point Inhibitors Combined With Chemotherapy, With or Without Bevacizumab, In Patients With Metastatic, Persistent Or Recurrent Cervical Cancer","status":"RECRUITING","sponsor":"N.N. Alexandrov National Cancer Centre","startDate":"2025-07-01","conditions":"Metastatic Cervical Cancer, Persistent Cervical Cancer, Recurrent Cervical Cancer","enrollment":120},{"nctId":"NCT07252739","phase":"PHASE2","title":"KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2025-12-19","conditions":"Malignant Neoplasm","enrollment":130},{"nctId":"NCT06445972","phase":"PHASE1, PHASE2","title":"Substudy 06D: Combination Therapies in Second Line (2L) Gastroesophageal Adenocarcinoma (MK-3475-06D/Keymaker-U06)","status":"RECRUITING","sponsor":"Merck Sharp & Dohme LLC","startDate":"2024-08-07","conditions":"Gastroesophageal Junction, Gastroesophageal Adenocarcinoma, Esophageal Neoplasms","enrollment":210},{"nctId":"NCT06508463","phase":"PHASE1","title":"Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2024-01-05","conditions":"Peripheral T Cell Lymphoma, Relapsed Peripheral T-Cell Lymphoma, Peripheral T-Cell Lymphoma, Not Otherwise Specified","enrollment":21},{"nctId":"NCT03607890","phase":"PHASE2","title":"Study of Nivolumab and Relatlimab in Advanced Mismatch Repair Deficient Cancers Resistant to Prior PD-(L)1 Inhibitor","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2018-11-16","conditions":"Refractory MSI - H Solid Tumors Prior of PD-(L) 1 Therapy, MSI-H Tumors","enrollment":38},{"nctId":"NCT02648282","phase":"PHASE2","title":"Study With CY, Pembrolizumab, GVAX Pancreas Vaccine, and SBRT in Patients With Locally Advanced Pancreatic Cancer","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2016-07-18","conditions":"Pancreatic Cancer","enrollment":58},{"nctId":"NCT06264180","phase":"PHASE3","title":"VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3]","status":"RECRUITING","sponsor":"Replimune Inc.","startDate":"2024-07-11","conditions":"Advanced Melanoma","enrollment":400},{"nctId":"NCT07469306","phase":"PHASE2","title":"Short-Course RT Plus CAPOX and Tislelizumab vs Long-Course CRT Plus Tislelizumab for Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2026-08-10","conditions":"Locally Advanced Rectal Cancer","enrollment":130},{"nctId":"NCT04301778","phase":"PHASE2","title":"Durvalumab and SNDX-6532 Following Chemo or Radio-Embolization for Patients With Intrahepatic Cholangiocarcinoma","status":"COMPLETED","sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","startDate":"2021-08-24","conditions":"Unresectable Intrahepatic Cholangiocarcinoma","enrollment":5},{"nctId":"NCT07319429","phase":"PHASE2, PHASE3","title":"Refining Fertility-sparing Treatment in Endometrial Carcinoma Based on Molecular Classification","status":"RECRUITING","sponsor":"Fudan University","startDate":"2026-01-25","conditions":"Endometrial Cancer, Fertility","enrollment":260},{"nctId":"NCT06704724","phase":"PHASE1","title":"A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2024-12-10","conditions":"Carcinoma, Pancreatic Ductal, Colorectal Neoplasms, Carcinoma, Non-Small-Cell Lung","enrollment":30},{"nctId":"NCT05935098","phase":"PHASE1","title":"BGB-A3055 Alone and in Combination With Tislelizumab in Participants With Solid Tumors","status":"TERMINATED","sponsor":"BeiGene","startDate":"2023-08-21","conditions":"Advanced Solid Tumor, Metastatic Solid Tumor, Solid Tumor","enrollment":99},{"nctId":"NCT07471165","phase":"PHASE2","title":"A Prospective, Single-Arm, Phase II Study: PD-L1 Monoclonal Antibody + Chemoradiotherapy as Bridge Therapy to Liver Transplantation for Locally Advanced Perihilar Cholangiocarcinoma (ACHIEVE-LT)","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2026-03-01","conditions":"Locally Advanced Perihilar Cholangiocarcinoma","enrollment":25}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":2612,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Sintilimab","Camrelizumab","Toripalimab","PD-1 Inhibitors","SHR-1210"],"phase":"phase_3","status":"active","brandName":"PD-1 antibody","genericName":"PD-1 antibody","companyName":"Sun Yat-sen University","companyId":"sun-yat-sen-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"A PD-1 antibody blocks the interaction between PD-1 on T cells and PD-L1/PD-L2 on tumor cells, releasing immune checkpoint inhibition and allowing T cells to recognize and attack cancer. Used for Advanced or metastatic solid tumors (specific indications under investigation in phase 3).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":26,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}